H3 Biomedicine

Scrip Asks…What Does 2022 Hold For Biopharma? Part 5: Clinical Trials

The COVID-19 pandemic drove huge shifts in clinical trial practice and the transformation is expected to continue even after the… Read More

H3 Biomedicine Welcomes Dr. Richard Woodman to its Board of Directors

Read More

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

Read More

H3 Biomedicine Presents Investigational Data Update on H3B-6545 for Treatment of Locally Advanced or Metastatic Estrogen Receptor- positive, HER2-negative Breast Cancer at San Antonio Breast Cancer Symposium

Read More

H3 Biomedicine Presents Update on Intratumoral E7766 Clinical Program for Advanced Solid Tumors or Lymphomas at AACR-NCI-EORTC Conference

Read More

Structural basis of intron selection by U2 snRNP in the presence of covalent inhibitors

Intron selection during the formation of prespliceosomes is a critical event in pre-mRNA splicing. Chemical modulation of intron selection has… Read More

Chutes & Ladders

Eisai's cancer genomics drug discovery subsidiary, H3 Biomedicine, promoted Ping Zhu, Ph.D., to president and chief scientific officer, and Ross… Read More

Eisai subsidiary appoints new leadership

H3 Biomedicine, a cancer genomics-based drug discovery subsidiary company of Woodcliff Lake pharmaceutical company Eisai, appointed a new executive leadership… Read More

Eisai Announces New Executive Leadership Team at H3 Biomedicine

Read More

H3’s Data Centric Approach to Cancer Genomics

Lihua Yu began her training as a biomedical engineer during her undergraduate studies, but for her Ph.D. training, she chose… Read More